Updated findings from the TALAPRO-2 clinical trial reveal that combining talazoparib (Talzenna) and enzalutamide (Xtandi) as an initial treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival compared to enzalutamide alone. These results were presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Key Findings
- Improved Overall Survival: In the “all-comers” cohort (805 patients), the combination therapy extended median overall survival by 8.8 months, reaching 45.8 months compared to 37.0 months for enzalutamide alone. In the HRR-deficient cohort, patients lived a median of 14 months longer with the combination therapy—45.1 months versus 31.1 months.
- Radiographic Progression-Free Survival (rPFS): Earlier analyses showed that the combination therapy delayed cancer progression significantly in both HRR-deficient and non-deficient groups.
- Mechanism of Action: Talazoparib, a PARP inhibitor, disrupts DNA repair in HRR-deficient cancer cells, while enzalutamide blocks hormones that fuel tumor growth. Together, they target cancer cells more effectively.
Safety Profile
The combination therapy maintained a manageable safety profile. The most common side effect was anemia, which oncologists typically manage by adjusting talazoparib’s dosage.
Implications
These findings support talazoparib plus enzalutamide as a potential new standard of care for mCRPC patients, regardless of HRR mutation status. Further research is needed to determine how this approach fits into evolving treatment strategies for advanced prostate cancer.
Reference
